On August 6, 2024, Progyny Inc (PGNY, Financial) released its 8-K filing for the second quarter of 2024. Progyny Inc is a company specializing in fertility and family building benefits solutions, serving employers across various industries. The company provides treatment services (Smart Cycles), access to a network of high-quality fertility specialists, and active management of selective provider clinics.
Performance Overview
Progyny Inc (PGNY, Financial) reported revenue of $304.1 million for Q2 2024, an 8.8% increase from $279.4 million in Q2 2023. However, this fell slightly short of the analyst estimate of $305.42 million. The company's earnings per share (EPS) met the analyst estimate at $0.17, up from $0.15 in the same period last year.
Financial Achievements
Progyny Inc (PGNY, Financial) achieved a record quarterly Adjusted EBITDA of $54.5 million, a 15% increase from $47.5 million in Q2 2023. The Adjusted EBITDA margin improved to 17.9%, up from 17.0% in the prior year period. The company also reported a strong cash flow conversion rate, with net cash provided by operating activities amounting to $56.7 million.
Income Statement Highlights
| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Revenue | $304.1 million | $279.4 million |
| Gross Profit | $68.3 million | $60.6 million |
| Gross Margin | 22.5% | 21.7% |
| Net Income | $16.5 million | $15.0 million |
| EPS (Diluted) | $0.17 | $0.15 |
| Adjusted EBITDA | $54.5 million | $47.5 million |
| Adjusted EBITDA Margin | 17.9% | 17.0% |
Balance Sheet and Cash Flow
As of June 30, 2024, Progyny Inc (PGNY, Financial) had total working capital of approximately $356.9 million and no debt. The company reported cash and cash equivalents and marketable securities totaling $262.2 million, a decrease of $109.6 million from March 31, 2024, primarily due to stock repurchase activities. During Q2 2024, the company repurchased 5,593,128 shares for $159.8 million.
Key Metrics
The company had 463 clients as of June 30, 2024, compared to 384 clients as of June 30, 2023. The number of Assisted Reproductive Technology (ART) cycles performed increased to 15,562 from 14,771 in the same period last year. However, the utilization rate for all members slightly decreased to 0.55% from 0.57%.
Commentary
"The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healthy and within the range of our long-established patterns," said Pete Anevski, Chief Executive Officer of Progyny.
Analysis
Progyny Inc (PGNY, Financial) continues to show robust growth in revenue and profitability, driven by an increase in the number of clients and covered lives. The company's strong cash flow and lack of debt position it well for future growth and share repurchase activities. However, the slight shortfall in revenue compared to analyst estimates and the lower-than-expected revenue per utilizing member could pose challenges in the upcoming quarters.
For more detailed insights and analysis, visit GuruFocus.com.
Explore the complete 8-K earnings release (here) from Progyny Inc for further details.
